Document is current
Any future updates will be listed below
-
Authors
Fagan, Harry https://orcid.org/0000-0001-8573-3024
Jones, Edward
Baldwin, David S. https://orcid.org/0000-0003-3343-0907
- License Information
-
More Information
Article History
Accepted: 2 November 2022
First Online: 27 November 2022
Declarations
:
: No specific funding was provided for the publication of this article. HF was supported in this work by the University of Southampton National Institute of Health Research Academic Foundation Programme (August 2019–August 2021).
: DSB provided advice (July 2020, unpaid) to the pharmaceutical company Idorsia, which has developed an orexin receptor antagonist. HF and EJ have no conflicts of interests to declare.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the review conception and design. HF performed the literature searches. HF performed the data extraction and appraisal of included pre-clinical studies. HF and EJ performed the data extraction and appraisal of included clinical studies. The manuscript was first drafted by HF and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript and agree to be accountable for the work.
